ASTRO: Shorter Radiation Feasible for Low-, Intermediate-Risk Prostate Cancer
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
MONDAY, Oct. 16, 2023 -- At five years, five-fraction stereotactic body radiotherapy (SBRT) is noninferior to control radiotherapy for biochemical/clinical failure (BCF) in men with localized prostate cancer (LPCa), according to a study presented at the annual meeting of the American Society for Radiation Oncology (ASTRO), held from Oct. 1 to 4 in San Diego.
Nicholas van As, M.D., from the Royal Marsden NHS Foundation Trust in London, and colleagues randomly assigned (1:1) men with LPCa, stage T1 to T2 to SBRT (433 patients; 36.25 Gy/5f in one to two weeks) or control radiotherapy (CRT; 441 patients; 78 Gy/39f over 7.5 weeks or 62 Gy/20f in four weeks) to the planning target volume.
The researchers found that at a median follow-up of 73.1 months, the five-year BCF event-free rate was 94.6 percent for control radiotherapy and 95.7 percent for the SBRT groups. SBRT was noninferior to CRT (unadjusted hazard ratio, 0.74; 90 percent confidence interval, 0.47 to 1.17; P-value for noninferiority = 0.007). Compared with the control group, the estimated absolute differences in the proportion of patients who were event-free in the SBRT group at five years was 1.36 percent. Radiation Therapy Oncology Group (RTOG) grade 2 or worst (G2+) genitourinary toxicity at five years occurred in 3.2 percent of control patients and 5.5 percent of patients in the SBRT group. For RTOG G2+ gastrointestinal toxicity, there was no significant difference observed between the groups.
"The outcomes for patients in both study arms were better than we expected," van As said in a statement. "To be able to sit with a patient and say, 'We can treat you with a low-toxicity treatment in five days, and your chance of keeping the cancer at bay for five years is 96 percent' -- it's a positive conversation to have."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Recommendations Issued for Palliative RT for Symptomatic Bone Mets
THURSDAY, May 30, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online May 22 in Practical Radiation Oncology...
New Tool IDs Sexual Struggles in Female Partners of Prostate Cancer Patients
FRIDAY, May 24, 2024 -- The Sexual Concerns In Partners of Patients with Prostate cancer tool is a valid measure of sexual health in female partners of patients with prostate...
Plant-Based Diet May Aid Prostate Cancer Outcomes
FRIDAY, May 3, 2024 -- Consuming a primarily plant-based diet may be associated with better cancer-specific health outcomes among men with prostate cancer, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.